WallStSmart

Merck & Company Inc (MRK)vsNeuronetics Inc (STIM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 42821% more annual revenue ($66.57B vs $155.10M). MRK leads profitability with a 4.8% profit margin vs -19.6%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

STIM

Avoid

27

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 6.7Quality: 4.0
Piotroski: 4/9Altman Z: -3.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.76

$60.92 premium

UndervaluedFair: $82.84Overvalued
STIMUndervalued (+80.2%)

Margin of Safety

+80.2%

Fair Value

$9.10

Current Price

$2.80

$6.30 discount

UndervaluedFair: $9.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

STIM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

STIM4 concerns · Avg: 3.3/10
Price/BookValuation
12.2x4/10

Trading at 12.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$207.26M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-131.6%2/10

ROE of -131.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : STIM

STIM has a balanced fundamental profile.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : STIM

The primary concerns for STIM are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 4.85 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while STIM is a turnaround play — different risk/reward profiles.

STIM carries more volatility with a beta of 1.17 — expect wider price swings.

STIM is growing revenue faster at 9.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 27/100). STIM offers better value entry with a 80.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Neuronetics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.

Want to dig deeper into these stocks?